NeuroPace, Inc. (NPCE)

Market Cap	351.32M
Revenue (ttm)	79.91M
Net Income (ttm)	-27.14M
Shares Out	32.56M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,059
Open	10.31
Previous Close	10.43
Day's Range	10.31 - 10.85
52-Week Range	5.45 - 15.11
Beta	2.04
Analysts	Buy
Price Target	14.83 (+37.32%)
Earnings Date	May 7, 2025

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facil...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 22, 2021
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: NPCE
• Website: https://www.neuropace.com

Financial Performance

In 2024, NeuroPace's revenue was $79.91 million, an increase of 22.14% compared to the previous year's $65.42 million. Losses were -$27.14 million, -17.64% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for NPCE stock is "Buy." The 12-month stock price forecast is $14.83, which is an increase of 37.32% from the latest price.

Price Target

$14.83

(37.32% upside)

Analyst Consensus: Buy